Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society - 1 Jan 2022

Molenaar Remco J, Wilmink Johanna W

Abstract excerpt

Isocitrate dehydrogenase 1 and 2 (IDH1/2) are enzymes recurrently mutated in various types of cancer, including glioma, cholangiocarcinoma, chondrosarcoma, and acute myeloid leukemia. Mutant IDH1/2 induce a block in differentiation and thereby contribute to the stemness and oncogenesis of their cells of origin. Recently, small-molecule inhibitors of mutant IDH1/2 have been Food and Drug Administration-approved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Differentiation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Glioma Diagnosis and Treatment

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Neoplastic Stem Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 34967233
DOI: 10.1369/00221554211062499
PMCID: PMC8721574

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.PMID 34967233Read ↗

IDH mutation and cancer stem cell.Semantic proximity Read ↗

Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review.Semantic proximity Read ↗

IDH mutations in cancer and progress toward development of targeted therapeutics.Semantic proximity Read ↗

The implications of IDH mutations for cancer development and therapy.Semantic proximity Read ↗

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.Semantic proximity Read ↗

Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation.Semantic proximity Read ↗

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer TherapeuticsSemantic proximity Read ↗

Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms.Semantic proximity Read ↗

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.Semantic proximity Read ↗

Targeting isocitrate dehydrogenase (IDH) in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.